Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+80 28-DAY vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years who have achieved menarche and are willing to use an oral contraceptive for contraception,Treatment of menstrual disorders (off-label),Emergency contraception (off-label)
Prevention of pregnancy (FDA-approved)
One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: terminal elimination half-life of 5.3-10.5 hours; Mestranol (as ethinyl estradiol): terminal half-life of 7-20 hours. Clinically, steady state is achieved after 5-7 days of daily dosing; the half-life supports once-daily dosing for consistent hormonal levels.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Norethindrone undergoes hepatic metabolism via reduction and conjugation; major enzyme CYP3A4. Mestranol is rapidly demethylated to ethinyl estradiol, which undergoes hepatic metabolism via CYP3A4 and conjugation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Norethindrone is primarily excreted in urine (approximately 60%) and feces (approximately 40%) as glucuronide and sulfate conjugates. Mestranol is metabolized to ethinyl estradiol; ethinyl estradiol and its metabolites are excreted in urine (40%) and feces (60%).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 80-85% bound to albumin and SHBG; Mestranol (as ethinyl estradiol): 95-98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: Vd ~ 4.0 L/kg, indicating extensive tissue distribution; Mestranol (as ethinyl estradiol): Vd ~ 1.5-2.5 L/kg.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: oral bioavailability ~ 64%; Mestranol: rapidly metabolized to ethinyl estradiol, with combined effects providing oral contraceptive efficacy. Both components are administered orally.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required; use with caution in severe renal impairment (GFR <30 m L/min) due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute liver disease or decompensated cirrhosis (Child-Pugh class B or C). Use with caution in mild hepatic impairment (Child-Pugh class A) with monitoring.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for prepubertal females. Postmenarchal adolescents: same adult dosing; adjust if <45 kg with caution.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women due to increased risk of thromboembolism and lack of contraceptive benefit.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thrombotic and thromboembolic events (e.g., MI, stroke, VTE), especially in smokers >35 years and those with hypertension, diabetes, hyperlipidemia, or obesity. Discontinue if thrombotic event occurs. Hepatic neoplasia risk. Elevated blood pressure. Gallbladder disease. Carbohydrate/lipid effects. Worsening of depression. Fluid retention. Hereditary angioedema. Chloasma. Lens opacities. Discontinue if jaundice develops. Use caution with history of depression, diabetes, or familial hyperlipidemia.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis, thromboembolic disorders, cerebral vascular disease, or past history of these conditions. Known or suspected pregnancy. Liver tumor (benign or malignant) or active liver disease. Known or suspected carcinoma of the breast or endometrium. Undiagnosed abnormal genital bleeding. Hypersensitivity to any component. Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, dasabuvir, or glecaprevir/pibrentasvir.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. Grapefruit juice may slightly increase estrogen levels; moderate consumption is acceptable. Consistent dietary habits are recommended to maintain stable hormone levels.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. Contraindicated in pregnancy due to estrogen component (mestranol) and progestin (norethindrone). First trimester: increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second and third trimesters: potential for androgenic effects on female fetus (pseudohermaphroditism), and possible long-term effects from estrogenic activity. Not recommended for use during pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Mestranol and norethindrone are excreted into breast milk in small amounts. M/P ratio not reported. May reduce milk production and composition (decreased protein and fat content). Potential for adverse effects on the infant (e.g., jaundice, breast enlargement in males). Generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; drug is contraindicated during pregnancy. No dose adjustments recommended or studied. Pharmacokinetic changes in pregnancy (increased Volume of distribution, altered clearance) are relevant if accidental exposure occurs, but no dose guidance exists. Discontinue immediately upon suspected pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Combined hormonal contraceptive containing 1 mg norethindrone and 0.035 mg ethinyl estradiol. 28-day regimen with 21 active pills and 7 placebo pills. For patients with compliance concerns, consider a 24-day active regimen alternative. Not recommended for patients with migraine with aura or smokers over 35. Monitor blood pressure at baseline and annually. Counsel on increased VTE risk, especially in first year of use. Use with caution in patients with uncontrolled hypertension, diabetes with vascular disease, or history of DVT/PE.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time for full contraceptive efficacy.,If you miss a pill, refer to the package insert instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, usually improving within 3 months.,Do not smoke while taking this medication; smoking increases risk of serious cardiovascular events.,Report sudden severe headache, chest pain, shortness of breath, or leg swelling to your healthcare provider.,This does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention.,Inform your healthcare provider about all medications and supplements, as some may reduce effectiveness.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+80 28-DAY vs AFIRMELLE, answered by our medical review team.
NORINYL 1+80 28-DAY is a Oral Contraceptive that works by Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+80 28-DAY and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+80 28-DAY is: One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+80 28-DAY and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+80 28-DAY is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to estrogen component (mestranol) and progestin (norethindrone). First trimester: increased risk of congenital anomalies,. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.